Legal entity
All 1 tracked stories fall under one category: ip-patent. ACESOT-1051 is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. WEE1 kinase inhibitor program appears in 1 tracked Legal story from August 29, 2026. The tracked stories average 2 original sources each.
Last mentioned: 5d ago
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: ip-patent. ACESOT-1051 is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. WEE1 kinase inhibitor program appears in 1 tracked Legal story from August 29, 2026. The tracked stories average 2 original sources each.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 2 Legal stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering WEE1 kinase inhibitor program. Shared-story counts are live from our verified record — not editorial picks.
Aprea's latest disclosure outlines a multi-jurisdictional patent estate spanning 28 issued and 30 pending patents, with WEE1 filings extending to 2047. The move strengthens exclusivity and signals an aggressive IP-defense strategy in precision oncology.
Source: The Manila Times · Postregister
WEE1 kinase inhibitor program is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
